Fulcrum Therapeutics, Inc.
FULC
$6.92
-$0.51-6.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 0.00 | 80.00M | 80.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | 0.00 | 80.00M | 80.00M |
| Cost of Revenue | 3.45M | -6.33M | -5.99M | -1.72M | 4.65M |
| Gross Profit | -3.45M | 6.33M | 5.99M | 81.72M | 75.35M |
| SG&A Expenses | 28.67M | 29.11M | 29.97M | 33.39M | 36.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 84.77M | 81.51M | 82.71M | 90.40M | 99.83M |
| Operating Income | -84.77M | -81.51M | -82.71M | -10.40M | -19.83M |
| Income Before Tax | -74.88M | -71.11M | -73.22M | -510.00K | -9.73M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -74.88 | -71.11 | -73.22 | -0.51 | -9.73 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.88M | -71.11M | -73.22M | -510.00K | -9.73M |
| EBIT | -84.77M | -81.51M | -82.71M | -10.40M | -19.83M |
| EBITDA | -83.38M | -80.09M | -81.28M | -8.94M | -18.24M |
| EPS Basic | -1.18 | -1.18 | -1.21 | -0.05 | -0.20 |
| Normalized Basic EPS | -0.74 | -0.74 | -0.74 | -0.01 | -0.10 |
| EPS Diluted | -1.19 | -1.19 | -1.22 | -0.07 | -0.22 |
| Normalized Diluted EPS | -0.74 | -0.74 | -0.74 | -0.02 | -0.11 |
| Average Basic Shares Outstanding | 253.40M | 241.57M | 241.39M | 241.05M | 240.55M |
| Average Diluted Shares Outstanding | 253.40M | 241.57M | 241.39M | 242.43M | 241.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |